Lexington Hires Medical Device Reimbursement Experts

VANCOUVER, BC–(Marketwired – Dec 7, 2017) – Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce entry into a strategic business relationship with a San Francisco arm of Navigant Consulting Inc., formerly Quorum Consulting. 

The intent of the relationship is to work with the relevant authorities towards developing a coverage policy in support of the planned commercial rollout of Lexington’s HeartSentry endothelial function measurement product. 

Navigant Consulting is a specialized professional services firm based in Chicago, Illinois. The company has nearly 50 offices across the United States, Canada, Europe, Middle East and Asia. Navigant recently acquired Quorum Consulting, a San Francisco based specialist service provider with extensive experience in the field of medical device reimbursement and health economics. Services include a proven ability to define strategic business opportunities and of influencing global coverage and payment policies. For more information, visit: www.navigant.com

Lexington’s President Eric Willis comments, “As recently announced, we are moving ahead quickly towards the commencement of our HeartSentry pilot clinical research study designed to build the foundational dataset ultimately aimed at supporting FDA clearance. As we plan for market entry, we know that a key element to commercial success will come from fielding a product that meets the threshold for medical insurance coverage. Regulatory approval rarely guarantees payment coverage for new devices, so we are undertaking what we believe is the prudent strategy of beginning that process today. We are delighted to have the opportunity to work with the Navigant team and feel certain the advice and direction we receive will prove invaluable towards providing HeartSentry the best strategy for market introduction.” 

To find out more about Lexington Biosciences, interested readers are invited to visit our website and view our video featuring principal HeartSentry inventor Dr. Jonathan Maltz, Ph.D., which provides an excellent overview of our business proposition and opportunity ahead. Please also follow us on Facebook, Twitter and LinkedIn.

About Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium — the vital innermost lining of a person’s cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit: https://lexingtonbiosciences.com/.

Eric Willis
CEO & Director

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to the completion of the listing of the Company’s shares on the Canadian Securities Exchange and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Lexington Biosciences, Inc.
+1 (800) 320-2640

Renmark Financial Communications Inc.
Laura Welsh
Tel: (416) 644-2020 or (514) 939-3989